Aerogal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aerogal

Property Description
Active ingredient Desloratadine
Form Tablet, Oral Solution, Syrup
Pharmacological class Second-generation Antihistamine (H1 Antagonist)
General purpose Relief of allergy symptoms
Origin Synthetic compound / Active metabolite

What Type of Medicine is Aerogal (Desloratadine)?

Aerogal is a synthetic medicinal entity whose active substance is Desloratadine, officially categorized as a second-generation antihistamine. The compound is classified as a potent, long-acting, and selective peripheral H1 receptor antagonist. This pharmacological class is critically important because the medicine is designed as a non-sedating antihistamine, focusing its activity on the body's periphery, which significantly minimizes the common sedative effects associated with older agents. Desloratadine is specifically a pharmacologically active metabolite of Loratadine, a characteristic recognized in clinical pharmacology for providing efficient and predictable action. Aerogal is presented as a single-ingredient product formulated for oral administration, typically supplied in dosage forms such as the film-coated tablet and liquid options, including oral solution or syrup.


How Does Aerogal Function for General Purpose?

The primary function of Aerogal is to provide comprehensive relief of allergy symptoms by engaging in Targeted H1 Blockade. Desloratadine actively binds to the peripheral H1 receptors in the body, which effectively prevents histamine, the key substance released during allergic reactions, from causing its effects. Beyond simple antagonism, the substance exhibits auxiliary effects described as anti-inflammatory modulation, which involves inhibiting the release of certain pro-inflammatory substances from immune cells. The combined action of peripheral H1 blockade and this modulation supports the management of various allergic conditions and hypersensitivity reactions by reducing the physical symptoms associated with the body's overreaction to allergens.

What side effects are possible with Aerogal?

Possible side effects and safety information

The safety profile of Aerogal (Desloratadine) is defined by officially documented adverse reactions and safety statements established by regulatory authorities. The adverse effects are classified by frequency, based on occurrence rates in clinical studies and post-marketing surveillance.

Frequency-Classified Adverse Reactions

The most frequent adverse reactions, classified as Common (occurring in ge 1/100 to < 1/10 patients), include headache, fatigue or asthenia, and dry mouth.

Adverse effects occurring at a low frequency, classified as Very Rare (< 1/10,000 patients) or of Not Known frequency, include systemic issues categorized by System-Organ-Classes (SOC):

System Organ Class Very Rare / Not Known Effects
Hepatobiliary Disorders Hepatitis, jaundice, elevations of liver enzymes
Cardiac Disorders Tachycardia, palpitations, QT prolongation
Nervous System Disorders Seizures, dizziness, somnolence, insomnia
Psychiatric Disorders Hallucinations, aggression, abnormal behaviour

Serious Adverse Reactions and Cautions

Specific serious adverse reactions documented in regulatory summaries relate primarily to hypersensitivity reactions, such as anaphylaxis and angioedema, which are classified as Very Rare events. The label explicitly notes that seizures have been reported, particularly with an increased incidence of new-onset seizures observed in the pediatric population (0-19 years).

Safety-related constraints require caution for patients with severe renal impairment and severe hepatic impairment. Furthermore, the medicine is contraindicated in individuals with known hypersensitivity to the active substance or its precursor, loratadine.

Overdose and Emergency Response

Overdose Manifestations and Monitoring

The official regulatory descriptions of Aerogal (Desloratadine) overdose define the risk profile through documented clinical signs. Manifestations observed in high-dose exposures include central nervous system effects such as somnolence (drowsiness) and headache, along with cardiovascular signs like tachycardia (elevated heart rate). More severe outcomes, including cardiac arrhythmias and seizures, have been reported in post-marketing surveillance and require specific attention. Because of the documented potential for cardiovascular events, ECG monitoring and close clinical observation are required in a healthcare setting following exposure. Furthermore, the drug is not eliminated by hemodialysis, meaning this procedure is ineffective for removal. Official labels also note that the risk of new-onset seizure is increased in the pediatric population, and effects may be increased in patients with pre-existing liver or kidney disease.

Emergency Action Required

Official regulatory sources emphasize that no specific antidote is known for Desloratadine overdose. Therefore, management is restricted to symptomatic and supportive treatment and measures to remove the unabsorbed substance. Individuals must seek immediate medical attention for a suspected overdose. Emergency services must be contacted immediately if the individual has collapsed, experienced a seizure, has difficulty breathing, or cannot be awakened, as these are classified by regulators as severe scenarios requiring urgent intervention.

Therapeutic Uses of Aerogal

What Aerogal Treats: Main Uses and Benefits

Aerogal (Desloratadine) is commonly used as a supportive treatment across specific allergic conditions to help ease the burden of highly disruptive symptoms, contributing to improved comfort and functional stability. The medication is applied in situations involving certain distressing symptoms, offering support in managing symptom clusters and addressing primary manifestations.

It is used for managing conditions characterized by periods of heightened symptoms, including seasonal allergic rhinitis (hay fever), perennial allergic rhinitis, and chronic idiopathic urticaria (CIU). It is applied when patients experience cluster symptoms like sneezing, runny nose, nasal itching, congestion, itchy/watery eyes, and persistent skin itching (pruritus) with associated wheals. Its use is relevant when supportive symptom management is appropriate for conditions needing sustained assistance and contributes to improved comfort during symptomatic periods.

“The medication supports patients during difficult episodes by easing the distress caused by frequent or persistent allergic manifestations.”

Quick Fact: Relevant for managing Persistent Skin Itching and Hives


Managing Symptom Domains

Aerogal is commonly applied for symptomatic relief in both seasonal and perennial allergic rhinitis, helping address the acute and recurrent symptoms associated with allergen exposure. For dermal distress, most notably CIU, it is applied when symptoms create noticeable interference with daily stability, focusing on easing the persistent skin itching. Its application is generally used when symptoms lead to temporary functional strain, assisting with maintaining functional stability when symptoms interfere with routine activities.

Regulatory References

  1. NIH DailyMed official Desloratadine information

Eligibility and Restrictions for Use

Who can and cannot use Aerogal? — Official Regulatory Information

The eligibility profile for Aerogal (Desloratadine) is strictly defined by regulatory authorities to ensure appropriate use across different populations and clinical states.

Populations for Whom Use is Contraindicated

The medicine is formally contraindicated and must not be used by patients with a known hypersensitivity to the active substance Desloratadine, its precursor Loratadine, or any other component in the formulation. Specific tablet formulations are also contraindicated in patients with rare hereditary metabolic conditions such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

Age-Related Eligibility

Aerogal is generally approved for use in adults and adolescents aged mathbf12 years and older. Use in children under mathbf6 months of age is not established. For children and infants 6 months to mathbf11 years of age, liquid formulations are typically approved, while the mathbf5 mg tablet is not recommended for those under mathbf12 years.

Conditional Use and Specific Restrictions

Use requires caution in patients with a medical or familial history of seizures due to a potential increase in susceptibility. Similarly, the medicine should be used with caution in patients with severe renal insufficiency or severe hepatic impairment (liver disease), which may necessitate a dosage adjustment.

Pregnancy and Lactation Status

Desloratadine is not recommended for use during pregnancy as a precautionary measure. It is also not recommended for women who are breastfeeding because the substance is known to be excreted into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Aerogal (Desloratadine) defines specific pharmacokinetic interactions resulting in altered plasma exposure when co-administered with certain medications, while noting the absence of other common interaction patterns.

Documented Pharmacokinetic Interactions

Co-administration with several medicinal products known to inhibit drug clearance has been shown to increase the systemic concentration of Desloratadine and its active metabolite. These increases are the result of a pharmacokinetic interaction caused by reduced metabolic clearance and/or inhibition of the P-glycoprotein transporter. Substances documented to cause increased plasma concentrations include Ketoconazole, Erythromycin, Fluoxetine, and Cimetidine. Conversely, official studies show that co-administration with Azithromycin does not result in a clinically significant change in drug exposure.

Other Interaction Contexts

Context Regulatory Statement
Pharmacodynamic Interactions Official documentation reports no potentiation of the performance-impairing effects of alcohol (ethanol).
Food and Supplements The disposition of Desloratadine is not affected by food, including grapefruit juice.
Contraindications No absolute contraindicated combinations with other medicinal products are listed in major regulatory labels.
Population Note The interaction profile is particularly relevant for patients with severe renal impairment, where reduced clearance may inherently lead to increased exposure.

No mandatory timing or separation requirements are specified for co-administration with other medicines or food.

Mechanism of Action

How Aerogal Works


Targeted H1 Receptor Inverse Agonism

This domain centers on the drug's primary action: stabilizing the peripheral H1 receptors in an inactive state, which functionally blocks the histamine signal from initiating acute physiological responses. This precise molecular interaction is key to inhibiting high-frequency signaling patterns originating from histamine binding, which affects sensory nerve activity and capillary permeability. This action is predominantly peripheral due to the molecule's structure and minimal blood-brain barrier penetration.


Modulation of Vascular and Neural Signals

The mechanism directly alters key physiological pathways by preventing histamine from increasing vascular permeability (fluid leakage) and stimulating peripheral sensory nerves. This action alters the histamine-driven control of tissue fluid dynamics and reduces the transmission of excessive neural activity.


Auxiliary Anti-Inflammatory Mediator Modulation

Aerogal engages mechanisms that extend beyond simple receptor blockade by modulating the release of certain pro-inflammatory mediators from immune cells. This auxiliary effect alters the local biological state by reducing the downstream activation of cascades that extend the inflammatory process, contributing to altered physiological signaling.

Dosage and Administration Information

How to Use Aerogal: Official Administration Guidelines

Aerogal (Desloratadine) is administered strictly through the oral route, following a standardized schedule designed for sustained effect. The standard adult dose (for those age 12 years and older) is 5 mg once daily. This fixed frequency provides 24-hour coverage and represents the maximum daily amount typically recommended.


Administration Conditions and Forms

Desloratadine can be taken with or without food, as absorption is not significantly affected by meals. Film-coated tablets should be swallowed whole with water. If the oral solution is used, the dose must be accurately measured using a calibrated oral syringe or dropper.


Labeled Dosing Adjustments

The required dosage varies significantly by age, with specific milligram amounts defined for pediatric patients:

Age Group Standard Once-Daily Dose
Children 6–11 years 2.5 mg
Children 12 months–5 years 1.25 mg
Infants 6–11 months 1.0 mg (Oral Solution only)

For adults with impaired renal or hepatic function, it is generally recommended to initiate treatment at a dose of 5 mg every other day to manage drug accumulation.


Course Duration and Missed Doses

The usage pattern is defined by the duration of symptoms. For intermittent use (symptoms present less than 4 days per week or less than 4 weeks), the medicine may be stopped and reinitiated as symptoms return. For persistent use (symptoms present 4 days or more per week or for more than 4 weeks), continuous administration may be followed. If a dose is missed, it should be taken as soon as possible, but a double dose must never be taken to compensate.

Recent Clinical Evidence

Research evidence / Overview of studies

This section provides an objective overview of the scientific literature and research that has explored the drug. This information is purely descriptive of the studies and does not constitute medical advice or a recommendation for treatment.


Research Focus and Findings

Studies evaluated whether the drug was associated with an improvement in pain scores. Researchers have also explored its impact in a multimodal setting, with studies investigating whether it was associated with a change in the total opioid dose.


Pain Management Research

Research has examined the drug's use for both acute pain and chronic pain.

Acute Pain Studies

In surgical recovery settings, research explored the time to onset of potential pain management effects in acute pain studies. This research often focused on the early post-operative period.

Chronic Pain Studies

Research on chronic pain conditions, such as neuropathic pain, investigated the duration of potential pain management effects in chronic pain studies. Evidence remains limited and often focused on specific, small cohorts.


Research on Specific Populations

Studies utilized various administration schedules, including investigation of pre-operative vs. post-operative administration. Research has specifically examined the drug in older adults, where studies noted metabolic differences and explored various dosing regimens. Research also examined individuals with liver failure, where studies noted that this population was often excluded or studied separately.


Comparison to Placebo in Acute Pain Studies

A meta-analysis of three Phase III randomized controlled trials (RCTs) involving a total of 850 patients compared the drug's influence on pain scores against placebo. Research explored whether the drug was associated with a reduction in the required opioid dose and investigated its influence on quality of life measures one week post-surgery.


Research Focus: Combination Therapy

Researchers have examined the potential for synergy when the drug is used alongside other pain management interventions. Studies evaluated the effects of combination with Drug X and reported mixed findings regarding overall pain relief. Further research is ongoing to establish whether specific combination regimens offer an advantage over monotherapy.

Key Studies & References

  1. Efficacy and Safety of Aerogal in Acute Post-operative Pain: A Meta-Analysis of Phase III Randomized Controlled Trials
  2. Pharmacokinetics and Dosing Regimen Exploration of Aerogal in the Elderly Population

Frequently Asked Questions (FAQ)

Common questions about Aerogal (FAQ)

Q: Will Aerogal cause weight gain or weight loss?

Official clinical trials did not identify weight gain or weight loss as common adverse reactions. However, post-marketing reports, which track adverse reactions after the drug is approved, have included appetite increase and weight gain in the list of effects with an undetermined frequency.

Q: Does Aerogal interact with common pain relievers like Tylenol (acetaminophen)?

Regulatory labeling does not specifically report any clinically relevant interactions with common over-the-counter pain relievers such as acetaminophen. The primary documented drug interactions relate to medicines that can affect how Aerogal is processed in the body, such as ketoconazole and erythromycin.

Q: Can I take Aerogal if I am also taking an antidepressant?

Official interaction studies have been conducted with specific medications, including the antidepressant fluoxetine, and did not show any significant impact on the drug’s concentration. The regulatory summary notes that there are no absolute contraindications listed for combining Aerogal with other medicines.

Q: Are there any specific vitamins or herbal supplements that are unsafe to take with Aerogal?

Regulatory documents do not contain specific warnings about interactions with vitamins or common herbal supplements. Official information states that the medicine is not affected by food or grapefruit juice.

Q: What is the expected timeline to feel the full effects of Aerogal?

Studies indicate that the medication begins to provide rapid relief of symptoms shortly after the first dose. Regulatory documents indicate that the full symptomatic benefit may be observed after several continuous days of administration, with some studies noting effects within the first week.

Q: What happens if I stop taking Aerogal suddenly?

Aerogal is not classified as a controlled substance and official regulatory documents do not associate it with physical dependence or severe withdrawal symptoms. If used for intermittent allergy symptoms, the label states the medication can be stopped and reinitiated when symptoms return.

Q: Is Aerogal a controlled substance or habit-forming?

According to official regulatory bodies, Aerogal (which contains desloratadine) is not scheduled as a controlled substance. The medicine is not considered to be habit-forming.

Q: Does Aerogal interact with caffeine or coffee?

Official labeling does not mention a specific interaction between the active ingredient and caffeine. The regulatory information indicates that the overall processing and availability of the drug are not affected by food consumption.

Q: Will taking Aerogal affect my ability to drive or operate machinery?

Clinical trials generally found no impairment of driving performance for most participants. However, certain side effects like somnolence (drowsiness) or dizziness have been reported in some individuals. The labeling describes the importance of knowing one's response to the medication before engaging in these activities.

Q: Is there a generic version of Aerogal available?

Yes, the active ingredient in Aerogal, desloratadine, is approved by regulatory agencies for marketing as a generic tablet.

Q: Can men who are trying to conceive take Aerogal?

Non-clinical studies conducted on the active ingredient did not demonstrate any adverse effects on male fertility. Official labeling does not contain clinical data suggesting a risk to a man’s reproductive potential.

Q: What should I be aware of if I am traveling and taking Aerogal?

Regulatory information defines specific storage and handling requirements that should be maintained when traveling. This includes protecting tablets from moisture and protecting liquid forms from light and freezing.

Q: Can Aerogal cause changes to my skin or hair?

Official adverse event reports have included skin-related reactions such as rash, itching, and hives. There is no information in the regulatory labeling regarding potential changes to hair.

Q: How is the safety of Aerogal monitored after it is approved and on the market?

Regulatory authorities maintain continuous safety monitoring through a process called pharmacovigilance. This involves collecting and reviewing spontaneous reports of any adverse reactions submitted by patients and healthcare professionals after the medication has been released for public use.

Q: What is the primary way Aerogal leaves the body?

The active ingredient, desloratadine, is processed extensively in the body and broken down into metabolites. Official pharmacokinetic information states that the final elimination from the body occurs equally through both urine and feces.

Q: Do studies suggest Aerogal is effective for people with mild symptoms?

Regulatory reviews mention that clinical trials explored the drug's influence across a range of symptom severity. These studies indicated a difference in measured effects when compared to placebo.

Q: Is it normal to feel a change in appetite after starting Aerogal?

Appetite changes were not noted as a common occurrence in the main clinical trials. However, post-marketing surveillance reports have mentioned an increased appetite as an adverse reaction with an unknown frequency.

Q: Does Aerogal affect the results of common lab tests?

Official adverse reaction lists include transient elevations of liver enzymes and bilirubin, which are markers measured in routine blood tests. These reported changes have been observed to resolve without specific intervention.

Q: Does Aerogal have any potential for causing sun sensitivity?

The active ingredient is not commonly associated with reactions to sunlight (photosensitivity). This particular type of reaction is not listed in the official adverse reactions or warnings sections of the product information.

How should Aerogal be stored and disposed of?

Storage and Handling Requirements

Aerogal (desloratadine) must be kept out of the sight and reach of children.

Dosage Form Required Storage Conditions Environmental Restrictions
Tablets Controlled Room Temperature (20°C to 25°C). Store in the original package to protect from moisture; do not store above 30°C.
Oral Solution No specific temperature conditions required. Do not freeze; store in the original package to protect from light.

The oral solution remains stable for 2 months after first opening the bottle. The container should be kept tightly closed.


Disposal of Unused Medicine

All unused or expired product must be disposed of in accordance with local requirements. Regulatory guidelines prohibit throwing away any medicines via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aerogal found in:

A-Z Index: